Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Zeng, Daxiong; Wang, Changguo; Lei, Wei; Huang, Jianan; Jiang, Jian‐Hua

doi:10.18632/oncotarget.19908

Cited by 22 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also previously showed that lower-dose apatinib resulted in similar PFS to a higher dose, but with fewer adverse effects. 16,17 This was also indicated in two recent studies of lower-dose apatinib in patients with stable SCLC after induction chemotherapy. 20,21 Another report also indicated that >50% of patients required a dose reduction because of grade 3 or 4 toxicities at an initial dose of 500 mg/day.…”

Section: Discussionmentioning

confidence: 71%

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

et al. 2019

Self Cite

View full text Add to dashboard Cite

The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 71%

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“… 51 Therefore, to find a suitable second-line treatment, the trials on the treatment of EGFR wild-type lung cancer were launched. 52 , 53 A group of 16 patients were enrolled and administered apatinib 250–500 mg/day. Three patients exhibited a PR, and eight patients showed SD.…”

Section: The Clinical Research Regarding Apatinibmentioning

confidence: 99%

“…The median PFS was 4.4 months. 52 Thus, apatinib may be a choice for EGFR wild-type patients as a second-line treatment. Presently, the wide use of EGFR-TKIs in NSCLC caused excessive EGFR-TKI resistance.…”

Section: The Clinical Research Regarding Apatinibmentioning

confidence: 99%

Progress in the treatment of solid tumors with apatinib: a systematic review

Zhao

Zhang

2018

OTT

View full text Add to dashboard Cite

With the investigation of molecular targets, many agents, such as trastuzumab and ramucirumab, have attained a positive outcome in oncotherapy. Vascular endothelial growth factor (VEGF) is considered a potent factor in angiogenesis and plays an important role in the growth of tumors. Moreover, both VEGF and its receptor are usually excessively expressed in solid tumors and could be hopeful targets for the treatment of neoplasms. Apatinib (YN968D1) is an oral small-molecule tyrosine kinase inhibitor of VEGFR-2. By inhibiting several signaling transduction pathways, it restrains angiogenesis and subsequently controls tumorigenesis. According to current studies, apatinib shows promising application in various solid tumors as a post-second- and post-third-line treatment. It could significantly improve the median overall survival and progression-free survival of patients with tolerated adverse reactions. This paper aims to summarize the recent research on apatinib including the mechanism, pharmacokinetics, trials, adverse reactions, and prospect as a treatment.

show abstract

“…Lung cancer is the main cause of cancer-related death worldwide; it has long been the most common cancer and the leading cause of cancer-related death in China. 37 For NSCLC patients that do not harbor a genetic driver mutation, anticancer treatment after second-line chemotherapy is indicated if the ECOG PS is satisfactory. However, alternative third or subsequent-line therapeutic regimens are limited, and the efficacy is generally unsatisfactory.…”

Section: Discussionmentioning

confidence: 99%

Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non‐small cell lung cancer after second‐line chemotherapy treatment: A retrospective study

Zhang

Huang

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThis study was designed to assess the clinical efficacy and toxicity of apatinib (YN968D1) as third or subsequent‐line treatment for stage III/IV non‐small cell lung cancer (NSCLC).MethodsA total of 100 patients with advanced NSCLC who were treated with apatinib at a daily dose of 250/425/500 mg at Shandong Cancer Hospital from January 2016 to June 2018 were enrolled in our study. The objective response, disease control, and median progression‐free survival rates were reviewed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. The main adverse events were evaluated per the Common Terminology Criteria for Adverse Events version 4.0.ResultsAll patients were assessable for response. No complete responses were observed, 11 patients achieved a partial response, and 56 showed stable disease. The objective response rate was 11.0%, the disease control rate was 67.0%, and the median progression‐free survival was 2.93 months (95% confidence interval 2.07–3.87). In Cox regression analysis, the Eastern Cooperative Oncology Group performance status score (hazard ratio 1.799; P < 0.05) and smoking history (hazard ratio 1.958; P < 0.05) were predictive indicators for apatinib treatment efficacy. Treatment‐related adverse events were tolerated, predictable, reversible, and controllable.ConclusionApatinib was found to be both effective and safe in advanced NSCLC patients without a genetic driver mutation who experienced progression after two or more lines of chemotherapy treatment.

show abstract

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Cited by 22 publications

References 15 publications

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Progress in the treatment of solid tumors with apatinib: a systematic review

Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non‐small cell lung cancer after second‐line chemotherapy treatment: A retrospective study

Contact Info

Product

Resources

About